Ocean Properties

Ocean Biomedical is a biopharmaceutical company that operates using a unique venture-launch model to accelerate the development of promising academic research into clinical-stage therapies. The company partners with leading research universities, such as Brown and Yale, to license and advance high-potential candidates in oncology, fibrosis, and infectious diseases. Its current pipeline includes a first-in-class malaria vaccine targeting parasite egress and nutritional uptake, as well as monoclonal antibody therapies for non-small cell lung cancer and glioblastoma. Additionally, Ocean Biomedical is developing small molecule inhibitors for idiopathic pulmonary fibrosis. By bridging the gap between laboratory discovery and commercialization, the company aims to bring transformative treatments to market more efficiently.